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Most children with sickle cell disease (SCD) who might otherwise
be considered for curative hematopoietic cell transplantation (HCT)
lack a healthy matched related donor. Barriers to alternative donor
HCT for SCD include graft rejection, graft-versus-host disea-
se(GVHD) and regimen-related toxicities. To address these prob-
lems, we initiated a phase II trial of unrelated bone marrow or
cord blood transplantation (CBT) using a novel, alemtuzumab-
based, reduced intensity conditioning (RIC) regimen in children
with severe SCD. Here we report the results for the 8 children
who received unrelated CBT on this study. Patients were prepared
for HCT following alemtuzumab(10, 15 and 20 mg on day -21,
-20 and -19 respectively), fludarabine(30 mg/m2 day -8 to -4) and
melphalan(140 mg/m2 day -3). Cyclosporine or tacrolimus and my-
cophenolate were administered for GVHD prophylaxis. Donor/re-
cipient HLA match status was 5/6 in all patients based on low/
intermediate resolution molecular typing at HLA -A, -B, and high
resolution typing at -DRB1. Median recipient age was 13.7 years
(range 7.4 to 16.2 years). The median pre-cryopreservation total nu-
cleated cell dose was 6.4x107/kg (range 3.1 to 7.6) and the median
post-thaw infused CD34 cell dose was 1.5x105/kg (range 0.2 to
2.3). The conditioning regimen demonstrated a favorable safety pro-
file. All patients achieved an absolute neutrophil count.500/mm3 by
day 33 (median 22 days). Six of eight patients had a platelet recovery
to. 50,000/mm3 by day 100. Five patients had autologous hemato-
poietic recovery and three patients had sustained full donor engraft-
ment. Two of 3 engrafted patients developed grade II acute GVHD.
Of these, one developed extensive chronic GVHD that was fatal 14
months post-transplant. With a median follow up of 1.8 years (range
1 – 2.6), 7 patients are alive with a 1-year survival of 100% and 2 are
alive without graft failure or disease recurrence. Total nucleated or
CD 34+ cell dose, HLA mismatch or ABO mismatch were not cor-
related with graft rejection in this small series.
Conclusion: This RIC regimen was associated with a high rate of
graft rejection after unrelated CBT. The CBT arm has been closed,
but the trial remains open to enrollment for eligible patients with 8/8
HLA allele matched unrelated bone marrow donors. Novel ap-
proaches aimed at reducing graft rejection while minimizing toxicity
will be needed before RIC unrelated donorCBT can be widely adop-
ted for transplanting children with severe SCD.328
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Human transplantation of expanded HPCs resulting in durable,
robust donor myeloid and T-cell engraftment has yet to be reported.
We report here preliminary results of a pilot study of myeloablative
dual UCB transplantation where one UCB unit is expanded ex vivo
using the NiCord technology. The NiCord UCB graft consists of
an expanded AC133+ and a re-frozen unexpanded AC133- fraction.HPCs were expanded for 21 days in media containing hematopoietic
cytokines supplemented with nicotinamide (NAM), a vitamin B3 de-
rivative that delays differentiation and improves engraftment effi-
ciency of human HPCs. Patients were conditioned with total body
irradiation (1350cGy) and fludarabine 160mg/m2. Graft versus
host disease (GVHD) prophylaxis consisted of tacrolimus andmyco-
phenolate mofetil. Four patients (median age 46; range 41-61) with
AML (n 5 2) or MDS (n 5 2) received a NiCord-containing dual
UCB graft. The unmanipulated unit was HLA 4/6 (n 5 3) or 5/6
(n 5 1) matched with the patient and contained a median cryopre-
served TNC dose of 3 x 107/kg. The expanded unit was 4/6 matched
(n5 2) or 5/6 HLA-matched (n5 2) with the patient and contained
a median cryopreserved TNC dose of 2.3 x 107/kg. After expansion
of the AC133+ cell fraction, theTNCandCD34+ cell dose increased
a median 455 fold (range 321-577 fold) and 75 fold (range 46-100
fold), respectively. Patients received the NiCord unit that contained
a median TNC and CD34+ cell dose of 3.1 x 107/kg (range 1.8-4.3)
and 4.6 x 106/kg, respectively. The transplanted negative fraction
contained a median of 1.8 x 105 (range 0.8-2.8) CD3+ T-cells/kg.
All patients are durably engrafted, with a median time to
ANC.500 of 13 days (range 11-18) and platelets .20,000 of 32
days (range 30-36). Peripheral blood CD3+ and CD15+ cell chime-
rism from the 4 patients at the time of last follow-up are reported.
Patient 1, day +280; CD3 (NiCord-2%, unmanipulated-80%,
host-18%), CD15 (NiCord-64%, unmanipulated-36%). Patient 2,
day +180; CD3 (NiCord-100%), CD15 (NiCord-100%). Patient
3, day +60; CD3 (NiCord-93%, host-7%), CD15 (NiCord-98%,
host-2%) Patient 4, day +60; CD3 (unmanipulated-100%), CD15
(unmanipulated-100%). There were no infusion-related or unex-
pected adverse events and all patients are alive and well without
GVHD. These data demonstrate prompt and prolonged engraft-
ment of both myeloid and lymphoid cells derived from expanded
HPCs (NiCord) in 3 of 4 patients treated to date. Longer follow-
up is required to confirm durability.329
SPACE AND TOLERANCE ARE CRITICAL FOR ENGRAFTMENT OF HEMATO-
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Total lymphoid irradiation (TLI) is a unique non-myeloablative
conditioning regimen for allogeneic hematopoietic cell transplanta-
tion (HCT) that targets major lymph node groups, but spares areas
of bone marrow (BM). Such radiation plus anti-thymocyte globulin
(ATG) create a tolerogenic host environment, permitting donor en-
graftment while ameliorating GVHD. Here we studied the role of
‘tolerance induction’, immune- and spatial barriers that hematopoi-
etic stem cells (HSC) encounter in mice conditioned with TLI/
ATG. 17x240 cGy TLI+3xATG were more lymphoablative than le-
thal total body irradiation (TBI). Lymphoablation was accompanied
by a proportional (but not absolute) increase of T regulatory cells
(Tregs) post-TLI/ATG. Long-term HSC (cKit+Sca+Lin-CD34-
Flt3-Slam+) were normal in number in unexposed legs, increased
in spleen and liver, but eradicated in irradiated spines. To segregate
the effects of host barriers from facilitating donor cells or graft vs
host reactivity, purified HSC (cKit+Thy1.1loSca-1+Lin-) were
used as grafts. Bioluminescence imaging revealed that across differ-
ent genetic barriers, overall, donor cell expansion was slower in TLI/
ATG vs TBI-treated hosts, and donor hematopoiesis was restricted
to exposed spine areas. FACS analyses confirmed that 4 wks after
TLI/ATG + congenic or minor antigen mismatched HCT hemato-
poiesis in the BM of shielded legs was fully host-derived, and only
areas within the TLI-field contained mixed donor/host chimerism,
including the HSC. The degree of donor chimerism differed be-
tween blood lineages, but remained stable over time. All T cell pro-
genitor stages in the thymus had similar proportions of donor
contribution, implying that the degree of donor chimerism is deter-
mined by the available space in the BM early post-TLI. The impor-
tance of tolerance-inducing host cells (Treg, NKT) was illustrated
using TLI/ATG-conditioned Rag2g-/- recipients (no NK, T, or B
cells), which, despite their lack of classical cellular immune barriers,
